[go: up one dir, main page]

US20020035734A1 - G-coupled receptor showing selective affinity for atp - Google Patents

G-coupled receptor showing selective affinity for atp Download PDF

Info

Publication number
US20020035734A1
US20020035734A1 US09/254,783 US25478399A US2002035734A1 US 20020035734 A1 US20020035734 A1 US 20020035734A1 US 25478399 A US25478399 A US 25478399A US 2002035734 A1 US2002035734 A1 US 2002035734A1
Authority
US
United States
Prior art keywords
receptor
cell
nucleic acid
drugs
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/254,783
Other languages
English (en)
Inventor
Didier Communi
Jean-Marie Boeynaems
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ogeda SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to EUROSCREEN S.A. reassignment EUROSCREEN S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOEYNAEMS, JEAN-MARIE, COMMUNI, DIDIER
Publication of US20020035734A1 publication Critical patent/US20020035734A1/en
Priority to US10/152,058 priority Critical patent/US7045345B2/en
Priority to US10/977,395 priority patent/US7288631B2/en
Priority to US10/976,678 priority patent/US7264940B2/en
Priority to US11/384,733 priority patent/US7485703B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Definitions

  • the present invention concerns a new G protein-coupled receptor having selective affinity for ATP and the nucleic acid molecule encoding said receptor, vectors comprising said nucleic acid molecule, cells transformed by said vector, antibodies directed against said receptor, nucleic acid probes directed against said nucleic acid molecule, pharmaceutical compositions comprising said products and non human transgenic animals expressing the receptor according to the invention or the nucleic acid molecule according to said receptor.
  • P2Y G protein-coupled P2 receptors
  • P2X P2X
  • the P2Y family encompasses selective purinoceptors (the P2Y 1 receptor activated by ATP and ADP), nucleotide receptors responsive to both adenine and uracil nucleotides (P2Y 2 receptor: activated equipotentally by ATP and UTP) and pyrimidinoceptors (the P2Y 3 and P2Y 6 receptors activated by UDP; the P2Y 4 ⁇ receptor: activated by UTP).
  • the P2Y 5 and P2Y 7 receptors display limited homologies with the other members of the P2Y family. They have been included in this family especially on the basis of radioligand binding studies showing affinities for adenine nucleotides (1-18).
  • the present invention concerns a new receptor having the amino acids sequence of FIG. 1 or any receptor which presents more than 50%, preferably more than 70%, more preferably more than 85%, more specifically more than 95% homology with the amino acids sequence of FIG. 1.
  • the present invention concerns also the receptor having at least the amino acids sequence of FIG. 1 or a portion thereof, preferably an amino acids sequence wherein the large extracellular part (the NH 2 portion of 450 amino acids sequence the end of which ( ⁇ ) is represented on FIG. 1) has been truncated or active parts of said portion such as the sixth and seventh transmembrane domains comprising the amino acids : His 686 , Arg 689 and Arg 728 .
  • the present invention is also related to said NH 2 portion of 450 amino acids sequence, including peptides reproducing or mimicking a portion of this sequence or of organic molecules sharing the effects of these peptides.
  • the inventors have discovered that either the whole receptor having the amino acids sequence of FIG. 1 or its portion (preferably the amino acids sequence wherein the large extracellular part of 450 amino acids has been truncated and starting from ( ⁇ ) in FIG. 1) seems to have the same industrial application (said portion will be identified hereafter as the P2Y11 receptor or sequence).
  • the first industrial application of this receptor or its portions is the screening of agonists and antagonists of said receptor which may have advantageous pharmaceutical or diagnostical properties.
  • the second industrial application of the receptor according to the invention or of its portions or of active parts of its portions is the identification of patients who may present genetic disorders induced by an inactive receptor or by an inactive portion of said receptor.
  • said receptor is a human receptor.
  • ATP seems to be the preferential natural agonist of this receptor : UTP, UDP, AP 4 A, AP 6 A, AMP and adenosine seem to be unable to stimulate the phosphoinositide pathway or were much less potent that ATP.
  • the invention is also related to a new G-coupled receptor, its portions or active parts of its portions having a selective affinity for ATP.
  • a selective affinity for ATP means that ATP is able to induce the formation of a functional response (preferably the accumulation of Inositol triphosphate IP 3 and a rise of intracellular Ca 2+ ) in a short time of incubation with said agonist (preferably in less than 5 min, more preferably less than 1 min) while the other known agonists of P2Y (UTP, UDP, AP 4 A, AP 6 A, AMP and adenosine were unable to stimulate said receptor or were much less potent than ATP and induce a detectable functional response by said receptor.
  • the present invention is also related to a nucleic acid molecule, such as a DNA molecule or an RNA molecule, encoding the receptor, its portions or active parts of its portions according to the invention.
  • said DNA molecule is a cDNA molecule or a genomic DNA molecule.
  • said nucleic acid molecule has more than 50l%, preferably more than 70%, more preferably more than 85%, more specifically more than 95% homology with the DNA sequence shown in FIG. 1.
  • the invention is related to a nucleic acid molecule which has more than 50%, preferably more than 70%, more preferably more than 85%, more specifically more than 95% homology with this DNA sequence (shown in the FIG. 1), wherein the DNA sequence encoding the 450 amino acids of the NH 2 portion were truncated.
  • the present invention is also related to the vector comprising the nucleic acid molecule according to the invention.
  • said vector is adapted for expression in a cell and comprises the regulatory elements necessary for expressing the amino acid molecule in said cell operatively linked to the nucleic acid sequence according to the invention as to permit expression thereof.
  • said cell is selected from the group consisting of bacterial cells, yeast cells, insect cells or mammalian cells.
  • the vector according to the invention is a plasmid or a virus, preferably a baculovirus, an adenovirus or a semliki forest virus.
  • the present invention concerns also the cell transformed by the vector according to the invention, said cell is preferably non-neuronal in origin and is selected from the group consisting of a COS-7 cell, a CHO cell, an LM(tk-) cell, an NIH-3T3 cell or a 1321N1 astrocytoma cell.
  • the present invention is also related to a nucleic acid probe comprising the nucleic acid molecule according to the invention, of at least 15 nucleotides capable of specifically hybridising with a unique sequence included in the sequence of the nucleic acid molecule encoding the receptor according to the invention.
  • Said nucleic acid probe may be a DNA or an RNA molecule.
  • the invention concerns also an antisense oligonucleotide having a sequence capable of specifically hybridising to an mRNA molecule encoding the receptor according to-the invention so as to prevent translation of said mRNA molecule or an antisense oligonucleotide having a sequence capable of specifically hybridising to the CDNA molecule encoding the receptor according to the invention.
  • Said antisense oligonucleotide may comprise chemical analogs of nucleotide or substances which inactivate MRNA, or be included in an RNA molecule endowed with ribozyme activity.
  • Another aspect of the present invention concerns a ligand (preferably an antibody) other than known molecules, especially the ATP, capable of binding to the receptor according to the invention and an anti-ligand (preferably also an antibody) capable of competitively inhibiting the binding of said ligand to the receptor according to the invention.
  • a ligand preferably an antibody
  • an anti-ligand preferably also an antibody
  • said antibody is a monoclonal antibody directed to an epitope of the receptor according to the invention and present on the surface of a cell expressing said receptor.
  • the invention concerns also the pharmaceutical composition
  • the pharmaceutical composition comprising an effective amount of oligonucleotide according to the invention, effective to decrease the activity of said receptor by passing through a cell membrane and binding specifically with MRNA encoding the receptor according to the invention in the cell so as to prevent its translation.
  • the pharmaceutical composition comprises also a pharmaceutically acceptable carrier capable of passing through said cell membrane.
  • the oligonucleotide is coupled to a substance, such as a ribozyme, which inactivates mRNA.
  • the pharmaceutically acceptable carrier comprises a structure which binds to a receptor on a cell capable of being taken up by cell after binding to the structure.
  • the structure of the pharmaceutically acceptable carrier in said pharmaceutical composition is capable of binding to a receptor which is specific for a selected cell type.
  • said pharmaceutical composition comprises an amount of the antibody according to the invention effective to block the binding of a ligand to the receptor according to the invention and a pharmaceutically acceptable carrier.
  • the present invention concerns also a transgenic non human mammal overexpressing (or expressing ectopically) the nucleic acid molecule encoding the receptor according to the invention.
  • the present invention also concerns a transgenic non human mammal comprising a homologous recombination knockout of the native receptor according to the invention.
  • the transgenic non human mammal whose genome comprises antisense nucleic acid complementary to the nucleic acid according to the invention is so placed as to be transcripted into antisense mRNA which is complementary to the mRNA encoding the receptor according to the invention and which hybridises to mRNA encoding said receptor, thereby reducing its translation.
  • the transgenic non human mammal according to the invention comprises a nucleic acid molecule encoding the receptor according to the invention and comprises additionally an inducible promoter or a tissue specific regulatory element.
  • the transgenic non human mammal is a mouse.
  • the invention relates also to a method for determining whether a ligand as an agonist or an antagonist of the receptor according to the invention can be specifically bound to said receptor; said method comprising the steps of contacting a cell or a cell extract from cells transfected with a vector according to the invention and expressing the nucleic acid molecule encoding said receptor, possibly isolating a membrane fraction from the cell extract, contacting the ligand with the membrane fraction or with the cell under conditions permitting binding of said ligand to the receptor and detecting, possibly by means of a bioassay such as a modification in the second messenger concentration or a modification in the cellular metabolism (preferably determined by the acidification rate of the culture medium), an increase in the receptor activity), thereby determining whether the ligand binds to the receptor, possibly as an agonist or as an antagonist of said receptor.
  • a bioassay such as a modification in the second messenger concentration or a modification in the cellular metabolism (preferably determined by the acidification rate of the culture medium), an increase in the receptor activity
  • the second messenger assay comprises measurement of intracellular cAMP, intracellular inositol phosphate (IP3), intracellular diacylglycerol (DAG) concentration or intracellular calcium mobilisation.
  • IP3 intracellular inositol phosphate
  • DAG diacylglycerol
  • the cell used in said method is a mammalian cell non neuronal in origin, such as a COS-7 cell, a CHO cell, a LM(tk-) cell an NIH-3T3 cell or 1321N1 cell.
  • the ligand is not previously known.
  • the invention is also related to the ligand isolated and detected by any of the preceding methods.
  • the present invention concerns also the pharmaceutical composition which comprises an effective amount of an agonist or an antagonist of the receptor according to the invention, effective to reduce the activity of said receptor and a pharmaceutically acceptable carrier.
  • the P2Y11 transcripts (obtained from the nucleotidic sequence starting from ( ⁇ ) in FIG. 1) are detectable in HL-60 human leukaemia cells. Expression of P2Y11 receptor mRNA is increased by agents (ripnoic acid, DMSO) known to induce the granulocytic differenciations of HL-60 cells. However, the P2Y11 transcripts could not be detected in mature neutrophils. Therefore, a first industrial application of the product according to the invention is the diagnostic of leukaemia, preferably by Northern blot analysis using the nucleotidic sequence encoding the P2Y11 receptor according to the invention.
  • agents ripnoic acid, DMSO
  • the present invention is also related to a diagnostic device or kit comprising the elements for the diagnostic of specific leukaemia, preferably HL-60 human leukaemia, comprising the receptor according to the invention, the nucleic acid sequence encoding said receptor, a nucleic acid probe comprising the nucleic acid molecule according to the invention of at least 15 nucleotides capable of specifically hybridising with a unique sequence included in the sequence of the nucleic acid molecule encoding the receptor according to the invention, such as an antisense oligonucleotide or a ligand such as an antibody, preferably a monoclonal antibody, capable of binding or competitively inhibiting the binding of a ligand to the receptor according to the invention.
  • Said diagnostic device or kit could be used for the specific diagnostic or for the monitoring of the evolution of tumoral cells, especially leukaemia HL-60 cells.
  • the previously described methods may be used for the screening of drugs (having advantageously anti-tumoral properties) which specifically bind to the receptor according to the invention.
  • Another industrial application of the present invention is related to the use of said drugs, preferably ligands or anti-ligands according to the invention, for the prevention and/or the treatment of specific diseases such as neutropenie or agranulocytose infections or cancer.
  • the invention is also related to the drugs isolated and detected by any of these methods.
  • the present invention concerns also a pharmaceutical composition
  • a pharmaceutical composition comprising said drugs and a pharmaceutically acceptable carrier.
  • the invention is also related to a method of detecting expression of a receptor according to the invention by detecting the presence of mRNA coding for a receptor, which comprises obtaining total RNA or total MRNA from the cell and contacting the RNA or mRNA so obtained with the nucleic acid probe according to the invention under hybridising conditions and detecting the presence of mRNA hybridised to the probe, thereby detecting the expression of the receptor by the cell.
  • hybridisation conditions above-described are preferably standard stringent conditions as described by Sambrook et al. ( ⁇ 9.47-9.51 in Molecular Cloning Laboratory Manual, Cold Spring Harbour, Laboratory Press, New York (1989)).
  • the present invention concerns also a method for diagnosing a predisposition to a disorder associated with the activity of the receptor according to the invention. Said method comprises:
  • nucleic acid probe capable of specifically hybridising to said nucleic acid molecule and labelled with a detectable marker
  • a last aspect of the present invention concerns a method of preparing the receptor according to the invention, which comprises:
  • step b incubating the cell of step b under conditions allowing the expression of the receptor according to the invention
  • FIG. 1 represents the nucleotide and deduced amino acid sequence of the new human P2Y receptor.
  • the putative phosphorylation sites by protein kinase C or by calmodulin-dependent protein kinases are indicated respectively by a black circle ( ⁇ ) or a black diamond ( ⁇ ).
  • the potential N-glycosylation site is indicated by a black square ( ⁇ ).
  • FIG. 2 represents dendrogram of the structural relatedness of the P2Y 11 receptor with the other P2Y subtypes.
  • the plot was constructed using the multiple sequence alignment program Pileup of the GCG package
  • the P2Y 5 -like published sequence (18) is identical to the P 2 Y 9 sequence submitted to the GenBank/EMBL Data Bank.
  • FIG. 3 represents Northern blot analysis of P2Y 11 messenger expression.
  • Each lane of the MTN blot contains 2 of polyA + RNA from several human tissues.
  • Each lane of the HL-60 blot contains 10 ⁇ g of total RNA from differentiated or undifferentiated HL-60 cells. Hybridization with the probe was performed as described under Materials and Methods.
  • the pictures of the MTNII blot and the HL-60 blot were obtained respectively, from an autoradiography and from a PhosphorImager SI (Molecular Dynamics).
  • the 2 kb-length P2Y 11 transcripts are indicated by a black arrow.
  • FIG. 4 represents concentration-action curves of several nucleotides on IP3 and cAMP accumulation in cells transfected with the P2Y 11 receptor.
  • 1321N1 and CHO-K1 transfected cells were assayed for the accumulation of, respectively, IP 3 (A) or cAMP (B) in response to various concentrations of the following nucleotides: ATP, 2MeSATP, ADP and 2MeSADP.
  • Incubation times were 30 s for IP 3 measurements and 15 min for cAMP assays.
  • the data represent the means ⁇ S.D. of triplicate experimental points and are representative of two independent experiments.
  • Trypsin was from Flow Laboratories (Bioggio, Switzerland) .
  • Culture media, G418, fetal calf serum (FCS), restriction enzymes and Taq polymerase were purchased from GIBCO BRL (Grand Island, N.Y.).
  • the radioactive products myo-D-[2- 3 H]inositol (17.7 Ci/mmol) and [( ⁇ 32 P]ATP (800 Ci/mmol) were from Amersham (Ghent, Belgium) .
  • Dowex AG1X8 (formate form) was from Bio-Rad Laboratories (Richmond, Calif.) ATP, ADP, AMP, adenosine, UTP, UDP, AP 4 A, AP 6 A, all-trans retinoic acid (RA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) were obtained from Sigma Chemical Co. (St. Louis, Mo.). 2-methylthio-ATP (2MeSATP), 2-methylthio-ADP (2MeSADP) and 8 (p-sulfophenyl) theophylline were from Research Biochemicals International (Natick, Mass.). Forskolin was purchased from Calbiochem (Bierges, Belgium).
  • DMSO dimethyl sulfoxide
  • Rolipram was obtained from the Laboratoires Jacques Logeais (Trappes, France).
  • the HL-60 human cell line was obtained from the American Type Culture Collection (Rockville, USA).
  • the human genomic DNA library was from Stratagene (La Jolla, Calif.).
  • pEFIN3 is an expression vector obtained from Euroscreen (Brussels, Belgium). Multiple Human Tissues Northern blot (MTN) were from Clontech (Palo Alto, Calif.).
  • a human placenta cDNA library was screened at moderate stringency with an [ ⁇ 32 P] DATP labelled P2Y 4 receptor probe corresponding to a partial sequence covering the third to the seventh transmembrane segments. Three overlapping clones encoding a new G protein-coupled receptor were isolated, but did not contain the 3′ end of the coding region. A human genomic DNA library was then screened with this partial sequence to obtain the complete sequence of this new receptor.
  • the hybridization conditions for screening the two libraries were 6 ⁇ SSC (1 ⁇ SSC: 0.15 M NaCl, 0.015 M sodium citrate) and 40% formamide at 42° C. for 14 hours and the final washing conditions were 0.5 ⁇ SSC, 0.1% SDS at 60° C.
  • HL-60 cells Two blots of human organs (MTN I and MTN II: 2 ⁇ g polyA + RNA/lane) and a blot containing total RNA from differentiated and undifferentiated HL-60 cells (10 ⁇ g of total RNA/lane) were hybridized with a probe corresponding to the new receptor in order to characterize its tissue distribution.
  • the HL-60 cells were maintained in RPMI 1640 supplemented with 10% FCS, 5 mM L-glutamine, 50 U/ml penicillin and 50 ⁇ g/ml streptomycin at 37° C. with 5% CO 2 .
  • the HL-60 cells were incubated during six days with or without 1 ⁇ M retinoic acid or 1.25% DMSO or during eight hours with 25 nM TPA.
  • the RNA from the differentiated or undifferentiated HL-60 cells was prepared with the RNeasy kit (Quiagen)
  • the blots were prehybridized 8 hours at 42° C. in a 50% formamide, 2% SDS solution and hybridized for 18 hours in the same solution supplemented with the [ ⁇ 32 P] labelled probe.
  • the final washing conditions were 0.1 ⁇ SSC and 0.1% SDS at 55° C.
  • the blots were exposed during twelve days and visualized as an autoradiography or using the PhosphorImager SI (Molecular Dynamics).
  • the complete sequence of the new receptor according to the invention was subcloned between the Hind III and Nhe I sites of the bicistronic pEFIN3 expression vector.
  • 1321N1 and CHO-K1 cells were transfected with the recombinant pEFIN3 plasmid or with the plasmid alone using the calcium phosphate precipitation method as described (19).
  • the transfected cells were selected with 400 ⁇ g/ml G418 in complete medium (10% FCS, 100 units/ml penicillin, 100 ⁇ g/ml streptomycin and 2.5 ⁇ g/ml amphotericin B in Dulbecco's modified Eagle's medium (DMEM)) two days after transfection and maintained in the same medium (10).
  • DMEM Dulbecco's modified Eagle's medium
  • IP Inositol phosphates
  • 1321N1 cells were labelled for 24 hours with 10 mCi/ml [ 3 H] inositol in inositol free DMEM containing 5% FCS, antibiotics, amphotericin, sodium pyruvate and 400 ⁇ g/ml G418.
  • Cells were washed twice with Krebs-Ringer Hepes (KRH) buffer of the following composition (124 mM NaCl, 5 mM KCl, 1.25 mM MgSO 4 , 1.45 mM CaCl 2 , 1.25 mM KH 2 PO 4 , 25 mM Hepes (pH:7.4) and 8 mM glucose) and incubated in the same medium for 30 min.
  • the cells were then challenged by various nucleotides for 30 s. The incubation was stopped by the addition of an ice cold 3% perchloric acid solution. IP were extracted and separated on Dowex columns as previously described (20).
  • CHO-K1 or 1321N1 cell lines were spread on Petri dishes (150.000 cells per dish) and cultured in Ham's F12 or DMEM medium containing 10% FCS, antibiotics, amphotericin, sodium pyruvate and 400 ⁇ g/ml G418.
  • Cells were preincubated for 30 min in KRH buffer with rolipram (25 ⁇ M) and incubated for different times in the presence of the agonists (15 min in most experiments). The incubation was stopped by the addition of 1 ml HCl 0.1 M. The incubation medium was dried up, resuspended in water and diluted as required. Cyclic AMP was quantified by radioimnunoassay after acetylation as previously described (21).
  • a human cDNA placenta library was screened at moderate stringency with a human P2Y 4 probe.
  • Nine clones which hybridized weakly with the P2Y 4 probe were obtained, purified and analyzed. Six of them corresponded to the sequence of the P2Y 6 receptor (10) while three overlapping clones corresponded to a partial sequence encoding a new G protein-coupled receptor, displaying about 30% identity with the other P2Y receptors.
  • the partial open reading frame started with an ATG-codon in a Kozak consensus but the 3′ end was missing in all three cDNA clones.
  • the Inventors screened a human genomic DNA library using this partial sequence as a probe. Four overlapping genomic clones were obtained.
  • the gene encoding the new receptor contains an intron interrupting the coding sequence at the 5′ end of the gene. This intron separates the three first codons from the rest of the coding sequence. Beside these first codons, the four genomic clones contained the complete open reading frame including the 3′ end missing in the cDNA clones.
  • the full open reading frame appeared as 1113 base pairs (bp) long and encoded a protein of 371 amino acids containing one potential site for N-linked glycosylation and two potential sites for phosphorylation by protein kinase C or calmodulin-dependent protein kinases (FIG. 1).
  • the new receptor provisionally named P2Y 11 , displays significant homologies with the other P2Y receptors (FIG. 2). In particular, 33% and 28% amino acid identity were observed respectively with the human P2Y 1 and P2Y 2 receptors.
  • the tissue distribution of the new receptor transcripts was investigated by Northern blotting (FIG. 3) by using a probe corresponding to a partial sequence encoding transmembrane segments 3 to 7. The strongest signal was observed for human spleen and corresponded to a 2 kilobase (kb)-length messenger RNA (MTN II). A weaker signal was observed in small intestine (MTN II) All the lanes in MTN I (heart, - brain, placenta, lung, liver, skeletal muscle, kidney, pancreas) were negative. The Inventors also detected specific 2 kb-length transcripts in HL-60 cells.
  • the signal was very weak in the undifferentiated HL-60 cells but increased when the cells had been treated with retinoic acid or DMSO. No increase was observed when the HL-60 cells were stimulated with TPA. A weak non-specific hybridization with 18S rRNA was observed. These data were confirmed with a non-overlapping probe corresponding to the first 300 bp of the coding region, presenting limited homologies with the other P2Y subtypes.
  • the complete sequence of the new receptor was introduced in the pEFIN3 expression vector in order to transfect the 1321N1 astrocytoma cell line, used previously to characterize several P2Y subtypes (6, 10, 12)
  • the pool of G418-resistant clones was tested for its functional response to several nucleotides.
  • ATP 100 ⁇ M
  • IP 3 inositol trisphosphate
  • ADP, AMP, adenosine, UTP, UDP, AP 4 A and AP 6 A were inactive at the same concentration. All nucleotides were totally inactive on the cells transfected with the vector alone.
  • the effect of ADP and 2MeSADP were minimal.
  • Pertussis toxin 50 ng/ml; 24 h pretreatment
  • had no effect on the ATP response whereas a lower concentration of pertussis toxin was previously shown to abolish the response to UTP in P2Y 4 transfected 1321N1 astrocytoma cells (22).
  • a response to ATP (10 ⁇ M) was also obtained following [Ca 2+ ] i measurements performed on the 1321N1 transfected cells while ADP was inactive at this concentration.
  • the 1321N1 cells transfected with the new receptor displayed a strong cAMP increase in response to ATP.
  • a much lower but significant endogeneous response due to the degradation of adenine nucleotides into adenosine was also obtained in the 1321N1 cells transfected with the vector alone.
  • the CHO-K1 cells express an endogeneous P2Y 2 receptor coupled to the phosphoinositide pathway (23) but do not possess adenosine receptors coupled to adenylyl cyclase. We therefore used CHO-K1 cells in order to characterize the coupling of the new receptor to the cAMP pathway.
  • a pool of G418 resistant CHO-K1 clones was first tested for its response to several nucleotides at a concentration of 100 ⁇ M. ATP was able to induce a strong increase in the cAMP content, whereas it was inactive on cells transfected with the vector alone. ADP, AMP, adenosine, UTP and UDP were completely inactive. Concentration-action curves were established for ATP, 2MeSATP, ADP and 2MeSADP (FIG. 4B). The rank order of potency was the same as in the inositol phosphate study on 1321N1 cells.
  • the receptor according to the invention presents some structural peculiarities which differentiate it from some other P2Y subtypes. Concerning its gene structure, the coding sequence is interrupted by an intron. Comparison between the cDNA and the genomic DNA sequences has clearly demonstrated the absence of intron in the coding region of the human P2Y 1 receptor (24, 25), the rat P2Y 2 receptor (26) and the rat P2Y 6 receptor (11). In terms of protein structure, the second and third extracellular loops are significantly longer than those of the other P2Y receptors. The homology with the other subtypes is relatively weak (about 30%). The closest G-coupled receptor is the human P2Y 1 receptor (33%) which is also a receptor responsive to adenine nucleotides (3, 4).
  • P2Y 1 -P2Y 8 eight P2Y receptor subtypes are described in the literature (P2Y 1 -P2Y 8 ) .
  • P2Y 9 and P2Y 10 two sequences related to the P2Y 5 receptor and named P2Y 9 and P2Y 10 , have been recently submitted to the GenBank/EMBL Data Bank.
  • the P2Y 9 sequence is identical to that recently published under the name “P2Y 5 -like” (18). Therefore the new receptor described in this paper might be called P2Y 11 .
  • P2Y 11 the new receptor described in this paper
  • P2Y 7 receptor is actually a receptor for leukotriene B 4 (16) and there is no functional evidence that the P2Y 5 and related receptors (P2Y 5 -like or P2Y 9 , P2Y 10 ) are nucleotide receptors (17, 18).
  • the P2Y11 subtype has the unique property to activate both the phosphoinositide and the cAMP pathways.
  • Other cloned P2Y receptors are coupled to phospholipase C exclusively.
  • the rank order of potency of agonists was the same for the two pathways. ATP was clearly much more potent than ADP. This difference may be even underestimated as a result of low level ATP contamination in ADP preparation or conversion of ADP into ATP during assays (4, 11).
  • 2MeSATP had the same maximal effect than ATP but presented a lower potency
  • 2MeSADP a potent activator of the P2Y 1 and P2T subtypes (4), was almost inactive.
  • the EC 50 values were comparable to those obtained in the study concerning the effects of extracellular nucleotides on the cAMP accumulation in the HL-60 cells (30).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
US09/254,783 1997-07-09 1998-07-09 G-coupled receptor showing selective affinity for atp Abandoned US20020035734A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/152,058 US7045345B2 (en) 1997-07-09 2002-05-21 G-coupled receptor showing selective affinity for ATP
US10/977,395 US7288631B2 (en) 1997-07-09 2004-10-29 G-coupled receptor showing selective affinity for ATP
US10/976,678 US7264940B2 (en) 1997-07-09 2004-10-29 G-coupled receptor showing selective affinity for ATP
US11/384,733 US7485703B2 (en) 1997-07-09 2006-03-20 Antibody against G-protein coupled receptor showing selective affinity for ATP and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97870101.9 1997-07-09
EP97870101 1997-07-09

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/BE1998/000108 Continuation WO1999002675A1 (fr) 1997-07-09 1998-07-09 Recepteur couple a la proteine g presentant une affinite selective pour l'atp et molecule d'acide nucleique codant ce recepteur
PCT/BE1998/000108 A-371-Of-International WO1999002675A1 (fr) 1997-07-09 1998-07-09 Recepteur couple a la proteine g presentant une affinite selective pour l'atp et molecule d'acide nucleique codant ce recepteur

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/152,058 Continuation US7045345B2 (en) 1997-07-09 2002-05-21 G-coupled receptor showing selective affinity for ATP
US11/384,733 Continuation US7485703B2 (en) 1997-07-09 2006-03-20 Antibody against G-protein coupled receptor showing selective affinity for ATP and uses therefor

Publications (1)

Publication Number Publication Date
US20020035734A1 true US20020035734A1 (en) 2002-03-21

Family

ID=8231018

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/254,783 Abandoned US20020035734A1 (en) 1997-07-09 1998-07-09 G-coupled receptor showing selective affinity for atp
US10/152,058 Expired - Lifetime US7045345B2 (en) 1997-07-09 2002-05-21 G-coupled receptor showing selective affinity for ATP
US10/976,678 Expired - Lifetime US7264940B2 (en) 1997-07-09 2004-10-29 G-coupled receptor showing selective affinity for ATP
US10/977,395 Expired - Fee Related US7288631B2 (en) 1997-07-09 2004-10-29 G-coupled receptor showing selective affinity for ATP

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/152,058 Expired - Lifetime US7045345B2 (en) 1997-07-09 2002-05-21 G-coupled receptor showing selective affinity for ATP
US10/976,678 Expired - Lifetime US7264940B2 (en) 1997-07-09 2004-10-29 G-coupled receptor showing selective affinity for ATP
US10/977,395 Expired - Fee Related US7288631B2 (en) 1997-07-09 2004-10-29 G-coupled receptor showing selective affinity for ATP

Country Status (9)

Country Link
US (4) US20020035734A1 (fr)
EP (2) EP0923644B1 (fr)
JP (1) JP2001500389A (fr)
AT (2) ATE321789T1 (fr)
CA (1) CA2263798C (fr)
DE (2) DE69813476T2 (fr)
DK (2) DK0923644T3 (fr)
ES (1) ES2260573T3 (fr)
WO (1) WO1999002675A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1398632A1 (fr) * 2002-09-11 2004-03-17 Bayer HealthCare AG Agonistes du récepteur p2y11 et utilisisation dans le domaine de l'érythropoièse

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034783A1 (fr) * 1998-12-08 2000-06-15 Smithkline Beecham Corporation Methodes de depistage d'agonistes et d'antagonistes du recepteur de hdpxu17
DE19860833C1 (de) 1998-12-30 2000-09-07 Albrecht E Sippel Methode zur zellulären High-Throughput(Hochdurchsatz)-Detektion von Rezeptor-Liganden-Interaktionen
US6787646B1 (en) * 1999-11-12 2004-09-07 Immusol, Inc. Tumor suppressor molecules and methods of use
AU2001239756A1 (en) * 2000-02-08 2001-08-20 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2001068842A2 (fr) * 2000-03-14 2001-09-20 Bayer Aktiengesellschaft Regulation de la proteine humaine gpcr similaire a p2y
US20030018989A1 (en) * 2001-03-29 2003-01-23 Brennan Thomas J. Transgenic mice containing GPCR5-1 gene disruptions
TW201629215A (zh) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 使用凝血酶之組成物及治療方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020045A2 (fr) * 1995-11-15 1997-06-05 Cor Therapeutics, Inc. Nouveau recepteur purinergique p2u2
US5891223A (en) * 1997-08-20 1999-04-06 Ultratech International, Inc. Multi-stage vent filter
US5981223A (en) * 1998-01-20 1999-11-09 Smithkline Beecham Corporation HDPXU17 encodes a novel 7-transmembrane receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1398632A1 (fr) * 2002-09-11 2004-03-17 Bayer HealthCare AG Agonistes du récepteur p2y11 et utilisisation dans le domaine de l'érythropoièse

Also Published As

Publication number Publication date
ATE237686T1 (de) 2003-05-15
US7264940B2 (en) 2007-09-04
US20050203282A1 (en) 2005-09-15
DE69813476D1 (de) 2003-05-22
DE69833988D1 (de) 2006-05-18
ATE321789T1 (de) 2006-04-15
EP1342729B1 (fr) 2006-03-29
DK0923644T3 (da) 2003-08-04
US20020142988A1 (en) 2002-10-03
DK1342729T3 (da) 2006-07-31
EP0923644A1 (fr) 1999-06-23
US20050158800A1 (en) 2005-07-21
US7045345B2 (en) 2006-05-16
DE69833988T2 (de) 2006-11-23
CA2263798A1 (fr) 1999-01-21
EP0923644B1 (fr) 2003-04-16
WO1999002675A1 (fr) 1999-01-21
EP1342729A2 (fr) 2003-09-10
JP2001500389A (ja) 2001-01-16
ES2260573T3 (es) 2006-11-01
US7288631B2 (en) 2007-10-30
CA2263798C (fr) 2011-03-29
EP1342729A3 (fr) 2003-09-17
DE69813476T2 (de) 2004-04-01

Similar Documents

Publication Publication Date Title
Noben-Trauth et al. A candidate gene for the mouse mutation tubby
Magyar et al. Myelin and lymphocyte protein (MAL/MVP17/VIP17) and plasmolipin are members of an extended gene family
JP2002501083A (ja) リガンド受容体およびそれらの使用
US20020035734A1 (en) G-coupled receptor showing selective affinity for atp
EP0862628B1 (fr) Recepteur et molecule d'acide nucleique codant ledit recepteur
JP2005509430A (ja) Ｇ蛋白共役型受容体をコード化する遺伝子およびその使用法
US7485703B2 (en) Antibody against G-protein coupled receptor showing selective affinity for ATP and uses therefor
US20090255004A1 (en) G-Protein Coupled Receptor and Uses Therefor
US20030166850A1 (en) Novel RGS9 protein binding interactions and methods of use thereof
EP1238078A2 (fr) Proteine transmembranaire clasp-4
WO2001042294A2 (fr) Proteine transmembranaire clasp-4
AU2002316176A1 (en) A G-protein coupled receptor and uses therefor
MXPA00007226A (en) Ligand receptors and uses therefor
MXPA00011048A (en) Nt2lp, novel g-protein coupled receptors having homology to neurotensin-2 receptors

Legal Events

Date Code Title Description
AS Assignment

Owner name: EUROSCREEN S.A., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COMMUNI, DIDIER;BOEYNAEMS, JEAN-MARIE;REEL/FRAME:010166/0149;SIGNING DATES FROM 19990526 TO 19990622

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE